The Eden Prairie, Minn.-based company said that Transmedic recently confirmed its first commercial orders in the region, coming in from both Singapore and Hong Kong.
The commercial orders were for both Aquadex FlexFlow consoles and the corresponding disposable products, CHF Solutions said.
“Our expansion into the Asian markets is a key factor in our commercialization strategy, and our distribution partner, Transmedic, has flawlessly initiated on executing that strategy. We believe the heart failure market for patients suffering from fluid overload remains largely untapped in Asia and that the Aquadex FlexFlow system provides a clinically proven alternative therapy option over pharmacotherapy,” chair & CEO John Erb said in a press release.
Last November, CHF Solutions closed its $18 million Series F convertible preferred stock and warrants round.